Pipeline

Alligators Bioscience’s portfolio comprise the drug candidates mitazalimab, ATOR-1017 and ALG.APV-527, as well as the drug concept Neo-X-Prime®, all of which are intended for the treatment of metastatic cancers.

The project AC101 (HLX22) is run by a partner, the Chinese company Shanghai Henlius Biotech Inc., who are responsible for financing and operating its clinical development.

Internal Programs

CD40
Solid metastatic tumors, initially Pancreatic Cancer
 
CD40, CEA(CAM5)
Solid metastatic tumors
 
4-1BB, 5T4
Solid metastatic tumors
 
4-1BB
Solid metastatic tumors
 
Undisclosed
Undisclosed
 

Partner Programs

Bispecific program no 1 with Orion Corporation
Undisclosed
Undisclosed
 
Bispecific program no 2 with Orion Corporation
Undisclosed
Undisclosed
 
Undisclosed
Undisclosed
 
HER2
Gastric cancer
 
Updated 2024-03-18